
Opinion|Videos|December 17, 2024
Premature Treatment Discontinuation (Time to Response)
Author(s)Darren M. Brenner, MD, Amy Ladewski, PA-C
Thought leaders explore premature treatment discontinuation and some of the reasons leading to it, such as time to response and safety in regards to the use of prescription therapies for IBS-C and CIC.
Advertisement
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Novo Nordisk Files NDA for CagriSema, Novel GLP-1-amylin Combination for Chronic Weight Management
2
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
3
Colorectal Cancer Screening in 2025: What Changed, and What Didn't, with Mark Fendrick, MD
4
Colonoscopy May be the Gold Standard, But Now It's a CRC Screening Bottleneck, Says Mark Fendrick, MD
5


















































































































































































































































































